INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21001, 10360, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21002, 10361, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21003, 10363, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21004, 10364, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21005, 11670, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21006, 14114, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21007, 15916, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21008, 16428, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21009, 21273, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21010, 25476, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21011, 25477, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21012, 25524, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21013, 25525, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21014, 25529, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21015, 25539, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21016, 25540, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21017, 25541, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21018, 25542, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21019, 25543, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21020, 25544, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21021, 25545, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21022, 25558, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21023, 25559, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21024, 25560, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21025, 25561, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21026, 25562, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21027, 25564, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21028, 25565, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21029, 25566, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21030, 25567, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21031, 25568, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21032, 26461, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21033, 26856, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21034, 26859, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21035, 26861, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21036, 26862, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21037, 27396, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21038, 27397, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21039, 28509, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21040, 31154, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21041, 33456, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21042, 33457, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21043, 1191, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21044, 1630, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21045, 4532, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21046, 5871, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21047, 7518, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21048, 10359, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21049, 10360, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21050, 10361, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21051, 10363, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21052, 10364, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21053, 11670, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21054, 14114, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21055, 15916, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21056, 16428, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21057, 21273, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21058, 25476, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21059, 25477, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21060, 25524, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21061, 25525, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21062, 25529, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21063, 25539, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21064, 25540, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21065, 25541, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21066, 25542, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21067, 25543, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21068, 25544, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21069, 25545, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21070, 25558, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21071, 25559, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21072, 25560, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21073, 25561, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21074, 25562, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21075, 25564, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21076, 25565, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21077, 25566, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21078, 25567, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21079, 25568, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21080, 26461, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21081, 26856, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21082, 26859, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21083, 26861, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21084, 26862, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21085, 27396, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21086, 27397, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21087, 28509, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21088, 31154, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21089, 33456, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21090, 33457, 'Quetiapine', 'Hypertension', 'The use of quetiapine may be associated with in increase systolic and diastolic blood pressure in children and adolescents.  During the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment with quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21091, 24433, 'Pyrazinamide', 'Gout', 'The use of pyrazinamide is contraindicated in patients with acute gout.  Pyrazinamide inhibits the renal excretion of uric acid, which may frequently result in precipitation or exacerbation of gout.  Therapy with pyrazinamide should be administered cautiously in patients with hyperuricemia or a history of gout.  Serum uric acid levels should be monitored regularly, and appropriate measures (e.g., administration of uricosuric agents) taken to prevent the development of gout.  If gouty arthritis occurs, pyrazinamide should be discontinued.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21092, 25515, 'Pyrazinamide', 'Gout', 'The use of pyrazinamide is contraindicated in patients with acute gout.  Pyrazinamide inhibits the renal excretion of uric acid, which may frequently result in precipitation or exacerbation of gout.  Therapy with pyrazinamide should be administered cautiously in patients with hyperuricemia or a history of gout.  Serum uric acid levels should be monitored regularly, and appropriate measures (e.g., administration of uricosuric agents) taken to prevent the development of gout.  If gouty arthritis occurs, pyrazinamide should be discontinued.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21093, 25516, 'Pyrazinamide', 'Gout', 'The use of pyrazinamide is contraindicated in patients with acute gout.  Pyrazinamide inhibits the renal excretion of uric acid, which may frequently result in precipitation or exacerbation of gout.  Therapy with pyrazinamide should be administered cautiously in patients with hyperuricemia or a history of gout.  Serum uric acid levels should be monitored regularly, and appropriate measures (e.g., administration of uricosuric agents) taken to prevent the development of gout.  If gouty arthritis occurs, pyrazinamide should be discontinued.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21094, 24433, 'Pyrazinamide', 'Liver Diseases', 'The use of pyrazinamide is contraindicated in patients with severe liver damage.  Pyrazinamide may cause hepatocellular injury, particularly in patients with underlying liver disease and during coadministration with other hepatotoxic agents including other antituberculous drugs such as isoniazid and rifampin.  Therapy with pyrazinamide should be administered cautiously and under strict medical supervision in patients with liver disease or a history of alcoholism.  Serum transaminases (ALT, AST) and bilirubin should be measured at baseline and monitored closely during therapy.  Patients should be instructed to discontinue the drug promptly and seek medical attention if signs and symptoms of hepatic injury develop, including fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.  To lessen the risk of hepatotoxicity, the maximum dosage should not exceed 2 g/day when treatment is administered daily or 3 g/day when administered twice weekly.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21095, 25515, 'Pyrazinamide', 'Liver Diseases', 'The use of pyrazinamide is contraindicated in patients with severe liver damage.  Pyrazinamide may cause hepatocellular injury, particularly in patients with underlying liver disease and during coadministration with other hepatotoxic agents including other antituberculous drugs such as isoniazid and rifampin.  Therapy with pyrazinamide should be administered cautiously and under strict medical supervision in patients with liver disease or a history of alcoholism.  Serum transaminases (ALT, AST) and bilirubin should be measured at baseline and monitored closely during therapy.  Patients should be instructed to discontinue the drug promptly and seek medical attention if signs and symptoms of hepatic injury develop, including fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.  To lessen the risk of hepatotoxicity, the maximum dosage should not exceed 2 g/day when treatment is administered daily or 3 g/day when administered twice weekly.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21096, 25516, 'Pyrazinamide', 'Liver Diseases', 'The use of pyrazinamide is contraindicated in patients with severe liver damage.  Pyrazinamide may cause hepatocellular injury, particularly in patients with underlying liver disease and during coadministration with other hepatotoxic agents including other antituberculous drugs such as isoniazid and rifampin.  Therapy with pyrazinamide should be administered cautiously and under strict medical supervision in patients with liver disease or a history of alcoholism.  Serum transaminases (ALT, AST) and bilirubin should be measured at baseline and monitored closely during therapy.  Patients should be instructed to discontinue the drug promptly and seek medical attention if signs and symptoms of hepatic injury develop, including fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.  To lessen the risk of hepatotoxicity, the maximum dosage should not exceed 2 g/day when treatment is administered daily or 3 g/day when administered twice weekly.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21097, 24433, 'Pyrazinamide', 'Kidney Diseases', 'The half-life of pyrazinamide may be prolonged in patients with renal impairment.  In addition, the drug''s metabolites, at least one of which is pharmacologically active, may accumulate.  Therapy with pyrazinamide should be administered cautiously in patients with renal dysfunction.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21098, 25515, 'Pyrazinamide', 'Kidney Diseases', 'The half-life of pyrazinamide may be prolonged in patients with renal impairment.  In addition, the drug''s metabolites, at least one of which is pharmacologically active, may accumulate.  Therapy with pyrazinamide should be administered cautiously in patients with renal dysfunction.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21099, 25516, 'Pyrazinamide', 'Kidney Diseases', 'The half-life of pyrazinamide may be prolonged in patients with renal impairment.  In addition, the drug''s metabolites, at least one of which is pharmacologically active, may accumulate.  Therapy with pyrazinamide should be administered cautiously in patients with renal dysfunction.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21100, 24433, 'Pyrazinamide', 'Diabetes Mellitus', 'The use of pyrazinamide may be associated with poor diabetic control.  Patients with diabetes mellitus should be monitored more closely during therapy with pyrazinamide, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
